Polio End-game Strategies - Poliovirus Type 2 Challenge Study

PHASE4CompletedINTERVENTIONAL
Enrollment

900

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

May 31, 2016

Conditions
Poliomyelitis
Interventions
BIOLOGICAL

IPV

IPV at birth, 6, 10, 14 weeks of age and tOPV at 18 and 22 weeks of age

BIOLOGICAL

bOPV

bOPV at birth, 6, 10, 14 weeks and tOPV at 18 and 22 weeks of age

BIOLOGICAL

bOPV and IPV

bOPV till week 10, bOPV+IPV at 14 and tOPV at 18 and 22 weeks of age

BIOLOGICAL

bOPV and IPV and IPV2

bOPV till week 10, bOPV+IPV at 14, tOPV+IPV2 at 18 and tOPV at 22 weeks of age

BIOLOGICAL

tOPV

tOPV till 22 weeks of age

Trial Locations (1)

Unknown

Rehri goth, Ibrahim Hyderi, Ali Akbar Shah, and Bhens Colony, Karachi

All Listed Sponsors
collaborator

World Health Organization

OTHER

collaborator

Centers for Disease Control and Prevention

FED

collaborator

National Institutes of Health (NIH)

NIH

lead

Aga Khan University

OTHER

NCT02189811 - Polio End-game Strategies - Poliovirus Type 2 Challenge Study | Biotech Hunter | Biotech Hunter